Fibroblast growth factor (FGF) 19 is an enterokine synthesized and released when bile acids
are taken up into the ileum. We show that FGF19 stimulates hepatic protein and glycogen …

Nonalcoholic fatty liver disease is strongly associated with hepatic insulin resistance (HIR);
however, the key lipid species and molecular mechanisms linking these conditions are …

Background No pharmacologic therapy has conclusively proved to be effective for the
treatment of nonalcoholic steatohepatitis, which is characterized by insulin resistance …

Nonalcoholic fatty liver disease (NAFLD) is recognized as the leading cause of chronic liver
disease in adults and children. NAFLD encompasses a spectrum of liver injuries ranging …

Inflammation may underlie the metabolic disorders of insulin resistance and type 2 diabetes.
IκB kinase β (IKK-β, encoded by Ikbkb) is a central coordinator of inflammatory responses …

Nonalcoholic fatty liver disease (NAFLD) is associated with obesity, insulin resistance, and
type 2 diabetes. NAFLD represents a large spectrum of diseases ranging from (i) fatty liver …

Background Obesity represents a risk factor for insulin resistance, type 2 diabetes mellitus,
and atherosclerosis. In addition, for any given amount of total body fat, an excess of visceral …

Background & Aims Pharmacologic treatments for nonalcoholic steatohepatitis (NASH) are
limited. Lifestyle interventions are believed to be effective in reducing features of NASH …

Insulin resistance is characteristic of obesity, type 2 diabetes, and components of the
cardiometabolic syndrome, including hypertension and dyslipidemia, that collectively …

Nonalcoholic fatty liver disease (NAFLD) is a risk factor for type 2 diabetes (T2D), but
whether NAFLD plays a causal role in the pathogenesis of T2D is uncertain. One proposed …